Connect your AI

Savara SVRA Increase (Decrease) in Prepaid Expense and Other Assets

Increase (Decrease) in Prepaid Expense and Other Assets at other companies

Zevra Therapeutics, Inc.ZVRA

-$2.05M-618%

Eton Pharmaceuticals, Inc.ETON

-$1.75M+41.0%

TRV

Trevi Therapeutics, Inc.TRVI

$2.84M+369%

PVL

Palvella TherapeuticsPVLA

$357K+144%

Amneal Pharmaceuticals, Inc.AMRX

$13.4M+2,512%

InsmedINSM

——

Other financials

Income statement

Revenue-—

Operating income-$39.0M-37.1%

Net income-$37.3M-40.0%

EPS (diluted)-$0.15-25.0%

Balance sheet

Cash & equivalents$38.8M+98.4%

Total debt$30.1M+1.8%

Total equity$176.0M+19.1%

Total assets$221.6M+17.1%

Cash flow

Operating cash flow-$33.0M-21.5%

CapEx$54.0K+1,700%

Free cash flow-$33.1M-21.7%

Valuation

Market cap$1.24B+247%

Enterprise value$1.23B+235%

P/S4,808.2×—

Profitability

Operating margin-19,183.3%—

Net margin-19,305.1%—

FCF margin-15,518.7%—

Returns & leverage

Return on equity-80%+4.7pp

Debt / equity0.2×0.0×

Current ratio13.5×-1.4×

Where this comes from

Reported directly by Savara in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets.

The official record: Savara’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Savara's increase (decrease) in prepaid expense and other assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Savara's increase (decrease) in prepaid expense and other assets?: Savara (SVRA) reported increase (decrease) in prepaid expense and other assets of $639K in Q1 2026.
How has Savara's increase (decrease) in prepaid expense and other assets changed year-over-year?: Savara's increase (decrease) in prepaid expense and other assets increased by 174.4% year-over-year, from -$859K to $639K.
What does increase (decrease) in prepaid expense and other assets mean?: This tracks changes in cash paid in advance for goods or services that will be consumed in future periods. It reflects the timing difference between cash outflows and the recognition of related expenses on the income statement.